Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: NANT study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study (041)
Authors:
- Yang YuYYYang Yu
- Wei ZhangWZWei Zhang
- Ronghua LiuRLRonghua Liu
- Wanying ShanWSWanying Shan
- Huayi LiHLHuayi Li
- Jiahao LiuJLJiahao Liu
- Bairong XiaBXBairong Xia
- Shanyang HeSHShanyang He
- Yu XiaYXYu Xia
- Siyuan WangSWSiyuan Wang
- Tian FangTFTian Fang
- Zhi WangZWZhi Wang
- 9 September 2022
- journal article
- abstracts
- Published by Elsevier in Gynecologic Oncology
- Vol. 166, S28-S29